DESIGN AND POWERING OF CYSTIC FIBROSIS CLINICAL TRIALS USING PULMONARY EXACERBATION AS AN EFFICACY ENDPOINT

BACKGROUND: Reduction in pulmonary exacerbations is an important efficacy endpoint for CF clinical studies. Powering exacerbation endpoints requires estimation of the future exacerbation incidence in CF study populations, but rates differ across the population. METHODS: We have estimated exacerbatio...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: VanDevanter, DR, Yegin, A, Morgan, WJ, Millar, SJ, Pasta, DJ, Konstan, MW
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079110/
https://ncbi.nlm.nih.gov/pubmed/21803665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2011.07.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky